TITLE

Insulin therapy for type 2 diabetes

AUTHOR(S)
Meneghini, Luigi
PUB. DATE
June 2013
SOURCE
Endocrine (1355008X);Jun2013, Vol. 43 Issue 3, p529
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Insulin therapy provides effective glycemic control in patients with diabetes who have deficient beta-cell function and insulin secretion. Subjects with type 2 diabetes not adequately controlled on oral agents or incretin therapies can initiate basal insulin replacement to correct fasting hyperglycemia. While all basal insulin preparations have similar efficacy in lowering fasting plasma glucose and improving A1C, the newer basal insulin analogs are associated with a lower risk of hypoglycemia than NPH insulin. Patients whose A1C levels remain above goal despite adequate basal insulin replacement need to evaluate and correct post-prandial hyperglycemia. With progressive beta-cell deficiency, rapid-acting insulin preparations can be introduced before one or more meals and titrated to achieve post-prandial glycemic control. For many patients requiring full basal/bolus insulin replacement, a strategy of fixed prandial insulin doses can yield acceptable glycemic control when compared to a more sophisticated approach utilizing carbohydrate counting and matching to insulin. Concentrated insulin preparations such as U-500 have also been of value in patients with resistant type 2 diabetes. Regardless of the type of insulin replacement used, the blood glucose lowering effects of insulin need to be carefully balanced with the increasing risk of hypoglycemia, and the weight gain associated with insulin intensification.
ACCESSION #
87303382

 

Related Articles

  • Attitudes Toward Diabetes Affect Maintenance of Drug-Free Remission in Patients With Newly Diagnosed Type 2 Diabetes After Short-Term Continuous Subcutaneous Insulin Infusion Treatment. Ailing Chen; Zhimin Huang; Xuesi Wan; Wanping Deng; Jiyan Wu; Licheng Li; Qiuling Cai; Haipeng Xiao; Yanbing Li // Diabetes Care;Mar2012, Vol. 35 Issue 3, p474 

    OBJECTIVE--Short-term intensive insulin treatment in patients with newly diagnosed type 2 diabetes can improve β-cell function and insulin sensitivity, which results in long-term remission without need for further antidiabetes medication. Patient attitudes toward their disease were assessed...

  • Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial). Umpierrez, Guillermo E.; Smiley, Dawn; Zisman, Ariel; Prieto, Luz M.; Palacio, Andres; Ceron, Miguel; Puig, Alvaro; Mejia, Roberto // Diabetes Care;Sep2007, Vol. 30 Issue 9, p2181 

    OBJECTIVE--We sought to study the optimal management of hyperglycemia in nonintensive care unit patients with type 2 diabetes, as few studies thus far have focused on the subject. RESEARCH DESIGN AND METHODS--We conducted a prospective, multicenter, randomized trial to compare the efficacy and...

  • Beating Diabetes. Akerfeldt, Mia // Australasian Science;Nov/Dec2008, Vol. 29 Issue 10, p26 

    The article discusses studies that show the potential of using phenyl butyric acid (PBA) to help treat Type 2 diabetes. The compound can help reduce the endoplasmic reticulum (ER) stress in the beta-cells which regulate blood glucose levels to make and release insulin. Research has shown that ER...

  • A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Mader, Julia K.; Lilly, Leslie C.; Aberer, Felix; Korsatko, Stefan; Strock, Ellie; Mazze, Roger S.; Damsbo, Peter; Pieber, Thomas R. // Diabetes Care;May2014, Vol. 37 Issue 5, p1476 

    OBJECTIVE This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twenty MDI-treated individuals with T2D with HbA1c ≤9% (75 mmol/mol) were enrolled in...

  • Cdk5 Inhibitory Peptide (CIP) Inhibits Cdk5/p25 Activity Induced by High Glucose in Pancreatic Beta Cells and Recovers Insulin Secretion from p25 Damage. Zheng, Ya-Li; Li, Congyu; Hu, Ya-Fang; Cao, Li; Wang, Hui; Li, Bo; Lu, Xiao-Hua; Bao, Li; Luo, Hong-Yan; Shukla, Varsha; Amin, Niranjana D.; Pant, Harish C. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Cdk5/p25 hyperactivity has been demonstrated to lead to neuron apoptosis and degenerations. Chronic exposure to high glucose (HG) results in hyperactivity of Cdk5 and reduced insulin secretion. Here, we set out to determine whether abnormal upregulation of Cdk5/p25 activity may be induced in a...

  • Combination sitagliptin/metformin improved beta cell function, HbA1c. Barzilai, Nir; Grassia, Tara; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p7 

    The article discusses a study which examined the effect of initial combination therapy with sitagliptin and metformin. Patients were randomly assigned to one of five treatment groups. Results showed that the therapy improved blood glucose levels and markers of beta cell function in patients with...

  • Goals of Treatment for Type 2 Diabetes. Marchetti, Piero; Lupi, Roberto; Del Guerra, Silvia; Bugliani, Marco; D'Aleo, Valentina; Occhipinti, Margherita; Boggi, Ugo; Marselli, Lorella; Masini, Matilde // Diabetes Care;Nov2009 Supplement, Vol. 32, pS178 

    The article discusses the possibility to treat type 2 diabetes by preserving β-cells and preventing the deterioration of glucose control. The findings of several studies on β-cell function among subjects with normal and impaired glucose tolerance are tackled. Also tackled are the effects...

  • Insulin for intensifying diabetes treatment. Meneghini, Luigi F. // Journal of Family Practice;Sep2011 Supplement 1, Vol. 60, pS21 

    The article presents a study on the role of insulin in diabetes treatment. It states that insulin is still an appropriate and essential option in the treatment of patients with failing β-cell functions and type 2 diabetes mellitus (T2DM). It mentions that several insulin analogues including...

  • Intensive Versus Conventional Insulin Therapy in Type 2 Diabetes Patients Undergoing D2 Gastrectomy for Gastric Cancer: A Randomized Controlled Trial. Shou-Gen Cao; Ren, Jian-A; Bo Shen; Dong Chen; Yan-Bing Zhou; Jie-Shou Li // World Journal of Surgery;Jan2011, Vol. 35 Issue 1, p85 

    Background: This study was to compare the effect of intensive insulin therapy (IIT) to conventional insulin therapy (CIT) on postoperative outcomes among type 2 diabetes mellitus (DM) patients who underwent D2 gastrectomy for gastric cancer. Methods: We randomly assigned gastric cancer patients...

Share

Other Topics